Shiming Peng, Xingyu Lin, Zongru Guo and Niu Huang Pages 1363 - 1375 ( 13 )
Despite the rapidly growing knowledge of functional and structural information regarding pharmaceutically relevant targets during the past decade, target-based drug discovery has remained a high-cost and low-yield process. Particularly, single-target drugs often turn out to be less effective in treating complicated diseases such as cancers, metabolic disorders and CNS diseases. However, discovering compounds that are effective against multiple desired targets raises an enormous challenge to the current mode of drug innovation. Computational chemogenomics approaches aim at predicting all potential interactions between small molecular ligands and biomolecular targets, thus the derived information can be directly applied to “design in” (i.e. engineer desirable binding spectrum) and “design out” (i.e. eliminate the unwanted interactions) specific biological activities. The present review will focus on introducing the recent methodological development and successful applications of structure-based and ligand-based approaches on predicting the ligand binding profiles, which is the very first and essential step toward rationally designing the multiple-target ligands. Structure-based methods (e.g. binding site mapping and inverse molecular docking) generally require the structures of known targets to navigate the receptor-ligand binding space, while ligand-based approaches (e.g. chemical similarity analysis and pharmacophore search) can only rely on the series of active compounds to derive the structural characteristics for describing certain biological activities.
binding free energy, chemoinformatics, computational chemogenomics, molecular docking, multiple-target ligand, pharmacophore search, similarity search, target-based drug discovery, CNS diseases, multiple desired targets
National Institute of Biological Sciences, Beijing, No. 7 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206, China.